Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes

• Published in: Breast (Edinburgh) Vol. 73; p. 103668
• Main Authors: Dimitrakopoulos, Foteinos-Ioannis, Goussia, Anna, Koliou, Georgia-Angeliki, Dadouli, Katerina, Batistatou, Anna, Kourea, Helen P., Bobos, Mattheos, Arapantoni-Dadioti, Petroula, Tzaida, Olympia, Koletsa, Triantafyllia, Chrisafi, Sofia, Sotiropoulou, Maria, Papoudou-Bai, Alexandra, Nicolaou, Irene, Charchanti, Antonia, Mauri, Davide, Aravantinos, Gerasimos, Binas, Ioannis, Res, Eleni, Psyrri, Amanda, Pectasides, Dimitrios, Bafaloukos, Dimitrios, Koumarianou, Anna, Bompolaki, Iliada, Rigakos, Georgios, Karanikiotis, Charisios, Koutras, Angelos, Zagouri, Flora, Gogas, Helen, Fountzilas, George
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-02-2024; Elsevier
• Subjects: CD8; Dose-dense chemotherapy; Early breast cancer; Original; Prognosis; TILs; Prognosis; TILs; Early breast cancer; CD8; Dose-dense chemotherapy
• ISSN: 0960-9776; 1532-3080
• DOI: 10.1016/j.breast.2023.103668

Dose-dense sequential (dds) chemotherapy has changed the clinical outcome of patients with early breast cancer (BC). To investigate the impact of dose intensity (DI) in the adjuvant setting of BC, this observational trial (HE 10/10) was conducted assessing the long-term survival outcome, safety and toxicity of a currently widely used chemotherapeutic regimen. In addition, the prognostic significance of tumor infiltrating lymphocytes (TILs) and infiltrating CD8+ lymphocytes were also evaluated in the same cohort.
Totally, 1054 patients were prospectively enrolled in the current study with 1024 patients being eligible, while adequate tissue was available for 596 of them. TILs, CD8+ lymphocytes in intratumoral areas in contact with malignant cells (iCD8), CD8+ lymphocytes in tumor stroma (sCD8) as well as the total number of CD8+ lymphocytes within the tumor area (total CD8) were assessed by immunohistochemistry.
Within a median follow-up of 125.18 months, a total of 200 disease-free survival (DFS) events (19.5%) were reported. Importantly, the 10-year DFS and OS rates were 78.4% (95% CI 75.0–81.5) and 81.7% (95% CI 79.0–84.1), respectively. Interestingly, higher CD8+ T cells as well as TILs in the tumor microenvironment were associated with an improved long-term survival outcome.
In conclusion, this study confirms the significance of dds adjuvant chemotherapeutic regimen in terms of long-term survival outcome, safety and toxicity as well as the prognostic significance of TILs and infiltrating CD8+ lymphocytes in BC patients with early-stage disease.
•Dose-dense sequential chemotherapy has changed the clinical outcome of patients with early breast cancer.•Its effectiveness has never been studied in conjunction with tumor microenvironment in a homogeneous population of Greek-Caucasian origin.•Long-term survival benefit in terms of DFS and OS as well as safety was confirmed.•Higher TILs and CD8-positive T cells in the tumor microenvironment were associated with an improved long-term survival outcome.